ATE405295T1 - Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine - Google Patents

Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine

Info

Publication number
ATE405295T1
ATE405295T1 AT03786493T AT03786493T ATE405295T1 AT E405295 T1 ATE405295 T1 AT E405295T1 AT 03786493 T AT03786493 T AT 03786493T AT 03786493 T AT03786493 T AT 03786493T AT E405295 T1 ATE405295 T1 AT E405295T1
Authority
AT
Austria
Prior art keywords
vectors
expression systems
raav
genetic modification
methods
Prior art date
Application number
AT03786493T
Other languages
English (en)
Inventor
Kenneth H Warrington
Shaun Opie
Nicholas Muzyczka
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Application granted granted Critical
Publication of ATE405295T1 publication Critical patent/ATE405295T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/858—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT03786493T 2002-05-01 2003-05-01 Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine ATE405295T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37731502P 2002-05-01 2002-05-01

Publications (1)

Publication Number Publication Date
ATE405295T1 true ATE405295T1 (de) 2008-09-15

Family

ID=32030574

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03786493T ATE405295T1 (de) 2002-05-01 2003-05-01 Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine

Country Status (11)

Country Link
US (2) US8802080B2 (de)
EP (1) EP1496944B1 (de)
AT (1) ATE405295T1 (de)
AU (1) AU2003295312B2 (de)
CA (1) CA2483624A1 (de)
DE (1) DE60323078D1 (de)
DK (1) DK1496944T3 (de)
HK (1) HK1071518A1 (de)
NZ (2) NZ561656A (de)
SI (1) SI1496944T1 (de)
WO (1) WO2004027019A2 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ561656A (en) 2002-05-01 2009-03-31 Univ Florida Improved rAAV expression systems for genetic modification of specific capsid proteins
US20060093589A1 (en) * 2004-02-19 2006-05-04 Warrington Kenneth H Vp2-modified raav vector compositions and uses therefor
US20040179028A1 (en) * 2003-03-12 2004-09-16 Fuji Photo Film Co., Ltd. Pixel defect correcting method, color mura correcting method and image display device
CA2500523A1 (en) * 2003-05-01 2004-11-18 University Of Florida Research Foundation, Inc. Vp2-modified raav vector compositions and uses therefor
EP1486567A1 (de) * 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verbesserter Adeno-assoziierter Virus (AAV)-Vektor für Gentherapie
ES2329636B2 (es) 2006-02-17 2010-07-26 Universitat De Valencia, Estudi General (Participa Con El 70%) Uso del factor pedf para inducir la auto-renovacion de celulas madre.
EP3492596A1 (de) 2007-04-09 2019-06-05 University of Florida Research Foundation, Inc. Raav-vektorzusammensetzungen mit tyrosinmodifizierten kapsidproteinen und verfahren zu deren verwendung
US9611302B2 (en) 2007-04-09 2017-04-04 University Of Florida Research Foundation, Inc. High-transduction-efficiency RAAV vectors, compositions, and methods of use
US9725485B2 (en) 2012-05-15 2017-08-08 University Of Florida Research Foundation, Inc. AAV vectors with high transduction efficiency and uses thereof for gene therapy
CN101951925A (zh) * 2008-02-20 2011-01-19 建新公司 血管发生抑制
CN102159713A (zh) 2008-05-20 2011-08-17 Eos神经科学公司 用于递送光敏蛋白的载体和使用方法
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
PT2403867T (pt) 2009-03-04 2019-08-29 Deutsches Krebsforsch Proteína de ativação de montagem (aap) e a sua utilização para o fabrico de partículas de parvovírus essenciais consistindo de vp3
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
MX359070B (es) 2010-12-01 2018-09-13 Alderbio Holdings Llc Composiciones anti-ngf y uso de las mismas.
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
EP2500434A1 (de) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsidfreie AAV-Vektoren, Zusammensetzungen und Verfahren zur Vektorherstellung und Genlieferung
EP3539568A1 (de) * 2011-11-22 2019-09-18 The Children's Hospital of Philadelphia Virusvektoren zur hocheffizienten transgenverabreichung
US10294281B2 (en) 2012-05-15 2019-05-21 University Of Florida Research Foundation, Incorporated High-transduction-efficiency rAAV vectors, compositions, and methods of use
KR102380265B1 (ko) 2013-07-22 2022-03-29 더 칠드런스 호스피탈 오브 필라델피아 변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
CN104592364B (zh) * 2013-10-30 2018-05-01 北京大学 定点突变和定点修饰的腺相关病毒、其制备方法及应用
US11185854B2 (en) * 2013-12-06 2021-11-30 Johnson Matthey Public Limited Company Cold start catalyst and its use in exhaust systems
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
CA2941640A1 (en) 2014-03-04 2015-09-11 University Of Florida Research Foundation, Inc. Improved raav vectors and methods for transduction of photoreceptors and rpe cells
IL292951B1 (en) 2014-05-02 2024-06-01 Genzyme Corp AAV vectors for gene therapy in the central nervous system and retina
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
PT3198018T (pt) * 2014-09-24 2021-02-24 Hope City Variantes dos vetores de vírus adenoassociados para edição do genoma de alta eficácia e métodos da mesma
CA2966620A1 (en) 2014-11-05 2016-05-12 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
SG11201703419UA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Modulatory polynucleotides
US10597660B2 (en) 2014-11-14 2020-03-24 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
EP3031820A1 (de) 2014-12-08 2016-06-15 Life Science Inkubator JC Polyomavirus virus-ähnliche Partikeln (VLP) mit einem Targeting-Peptid
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
US20180030096A1 (en) 2015-02-03 2018-02-01 University Of Florida Research Foundation, Inc. Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
WO2016133917A1 (en) 2015-02-16 2016-08-25 University Of Florida Research Foundation Raav vector compositions, methods for targeting vascular endothelial cells and use in treatment of type i diabetes
US10081659B2 (en) 2015-04-06 2018-09-25 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Adeno-associated vectors for enhanced transduction and reduced immunogenicity
JP6985250B2 (ja) 2015-05-16 2021-12-22 ジェンザイム・コーポレーション 深部イントロン突然変異の遺伝子編集
CN108138159A (zh) 2015-06-23 2018-06-08 费城儿童医院 经修饰的因子ix、以及用于基因转移到细胞、器官和组织的组合物、方法和用途
PT3356390T (pt) 2015-09-28 2021-04-21 Univ Florida Métodos e composições para vetores virais que se evadem a anticorpos
US20190071681A1 (en) * 2016-02-26 2019-03-07 University Of Florida Research Foundation, Incorporated Aav heparin mutants that display significantly improved eye and brain transduction
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (de) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
CN109476707B (zh) 2016-05-13 2022-12-02 4D分子治疗有限公司 腺相关病毒变体衣壳和其使用方法
SG11201809643UA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
KR102392236B1 (ko) 2016-05-18 2022-05-03 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
MX2019001938A (es) 2016-08-15 2019-07-04 Genzyme Corp Metodos para detectar aav.
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
WO2018075798A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
EA038695B1 (ru) 2017-02-15 2021-10-06 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Способы и композиции для переноса генов по сосудистой сети
CN110392607A (zh) * 2017-03-13 2019-10-29 三菱化学株式会社 过渡金属负载沸石和其制造方法以及氮氧化物净化用催化剂和其使用方法
CN110770346B (zh) * 2017-03-15 2024-01-12 北卡罗来纳-查佩尔山大学 多倍体腺相关病毒载体及其制备和使用方法
US10550405B2 (en) 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
CN110913866A (zh) 2017-05-05 2020-03-24 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2019018342A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. NETWORK EQUIPMENT TRACK GUIDE SYSTEM
UA127455C2 (uk) 2017-09-20 2023-08-30 4Д Молекьюлар Терапьютикс Інк. Капсид аденоасоційованого вірусу і спосіб його застосування
JP7502991B2 (ja) 2017-10-16 2024-06-19 ボイジャー セラピューティクス インコーポレイテッド 筋萎縮性側索硬化症（ａｌｓ）の治療
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
EP4219695A3 (de) 2017-11-27 2024-01-17 4D Molecular Therapeutics Inc. Kapside mit adeno-assoziierten virenvarianten und verwendung zur hemmung der angiogenese
WO2019158619A1 (en) * 2018-02-15 2019-08-22 Bjoerklund Tomas Modified viral capsids
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
JP2021522775A (ja) * 2018-05-07 2021-09-02 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 合理的なポリプロイド性アデノ随伴ウイルスベクターならびにその製造法および使用法
US11821009B2 (en) 2018-05-15 2023-11-21 Cornell University Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
US20210317478A1 (en) * 2018-08-21 2021-10-14 Massachusetts Eye And Ear Infirmary Compositions and methods for modulating transduction efficiency of adeno-associated viruses
US20220154211A1 (en) 2019-02-25 2022-05-19 Novartis Ag Compositions and methods to treat bietti crystalline dystrophy
MX2021010149A (es) 2019-02-25 2021-09-14 Novartis Ag Composiciones y metodos para tratar la distrofia cristalina de bietti.
CA3133453A1 (en) 2019-03-21 2020-09-24 Daniel Mccoy Recombinant adeno-associated virus vectors
US20210082541A1 (en) * 2019-08-31 2021-03-18 Wyatt Technology Corporation Measuring attributes of a viral gene delivery vehicle sample via separation
BR112022006530A2 (pt) 2019-10-17 2022-07-05 Stridebio Inc Vetores virais adenoassociados para o tratamento da doença de niemann-pick tipo c
WO2024006433A1 (en) * 2022-06-30 2024-01-04 Carnegie Mellon University Method for production of virus-like particles for gene delivery

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029469A2 (en) * 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5741683A (en) * 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
JP2001500376A (ja) * 1996-09-06 2001-01-16 カイロン コーポレイション 組換えａａｖベクターを使用する治療分子の肝臓特異的送達のための方法および組成物
US6221646B1 (en) * 1997-07-31 2001-04-24 Chiron Corporation Materials and methods for simplified AAV production
EP1183051A2 (de) 1999-03-15 2002-03-06 Chiron Corporation Verwendung von rekombinanten expressionsvektoren zur behandlung oder vorbeugung von augenkrankheiten
US6943153B1 (en) * 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6329181B1 (en) * 2000-08-07 2001-12-11 Neurologix, Inc. Helper functions for recombinant vector production
AU2001292881A1 (en) 2000-09-20 2002-04-02 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6962815B2 (en) * 2001-01-05 2005-11-08 Children's Hopital Inc. AAV2 vectors and methods
US6692815B2 (en) * 2001-06-15 2004-02-17 Vinylex Corporation Extruded plastic lumber and method of manufacture
US6723551B2 (en) * 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
US20060292117A1 (en) * 2002-04-17 2006-12-28 Loiler Scott A Improved rAAv vectors
NZ561656A (en) 2002-05-01 2009-03-31 Univ Florida Improved rAAV expression systems for genetic modification of specific capsid proteins
AU2003265855A1 (en) * 2002-08-28 2004-03-19 University Of Florida Modified aav
CA2500523A1 (en) 2003-05-01 2004-11-18 University Of Florida Research Foundation, Inc. Vp2-modified raav vector compositions and uses therefor

Also Published As

Publication number Publication date
HK1071518A1 (en) 2005-07-22
WO2004027019A2 (en) 2004-04-01
DK1496944T3 (da) 2008-12-01
NZ536274A (en) 2008-04-30
EP1496944A4 (de) 2006-03-22
SI1496944T1 (sl) 2009-02-28
US20060088936A1 (en) 2006-04-27
EP1496944B1 (de) 2008-08-20
NZ561656A (en) 2009-03-31
AU2003295312B2 (en) 2008-08-14
EP1496944A2 (de) 2005-01-19
US8802080B2 (en) 2014-08-12
WO2004027019A3 (en) 2004-08-05
US20150005369A1 (en) 2015-01-01
AU2003295312A1 (en) 2004-04-08
CA2483624A1 (en) 2004-04-01
DE60323078D1 (de) 2008-10-02

Similar Documents

Publication Publication Date Title
ATE405295T1 (de) Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine
PH12020550094A1 (en) Adeno-associated virus variant capsids and methods of use thereof
WO2005077333A3 (en) Gel-based delivery of recombinant adeno-associated virus vectors
WO2005005610A3 (en) Mutant adeno-associated virus virions and methods of use thereof
DK1783225T3 (da) Strukturprotein fra AAV, dets fremstilling og anvendelse
DE60033293D1 (de) Neue b7-4 moleküle und deren verwendungen
ATE360031T1 (de) Chimäre proteine und anwendungen
WO2003042362A3 (en) PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
WO2003088899A3 (en) Methods for the production of chimeric adeno-associated virus (aav) vectors, compositions of chimeric aav vectors, and methods of use thereof
MX2022002961A (es) Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept.
DE60031418D1 (de) 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen
ATE480620T1 (de) Neue pgc-1-isoformen und deren verwendungen
WO2002002148A3 (en) Dual recombinant gene therapy compositions and methods of use
WO2001083781A3 (en) 14094, a novel human trypsin family member and uses thereof
BR112022003206A2 (pt) Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte
DK1664315T3 (da) AAV-vektorer til in vivo genterapi af rheumatoid arthritis
DE60237236D1 (de) Ein mitglied der menschlichen proteinkinasefamilie, und verwendungen dafür
DE60234047D1 (de) 15603, ein mitglied der humanen ionenkanal-familie
WO2023010120A3 (en) Engineering aav vectors with improved cns targeting
WO2002016568A3 (en) 46863, a human methyltransferase and uses thereof
DE60136832D1 (de) Atcr-1, eine humane acyltransferase und verwendungen davon
AU2001288284A1 (en) 14189, a human kinase and uses thereof
WO2001075098A3 (en) 33166, a human hydrolase-like molecule and uses thereof
DE60120974D1 (de) Proteinkinase-molekül 14911 und dessen anwendungen
WO2001064908A3 (en) 14790, a protein kinase and uses therefor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties